Search Images Maps Play YouTube News Gmail Drive More »
Sign in
Screen reader users: click this link for accessible mode. Accessible mode has the same essential features but works better with your reader.

Patents

  1. Advanced Patent Search
Publication numberUSD457246 S1
Publication typeGrant
Application numberUS 29/115,771
Publication dateMay 14, 2002
Filing dateDec 20, 1999
Priority dateDec 20, 1999
Publication number115771, 29115771, US D457246 S1, US D457246S1, US-S1-D457246, USD457246 S1, USD457246S1
InventorsSidney Mazel, James M. Mundt
Original AssigneeMerck & Co., Inc.
Export CitationBiBTeX, EndNote, RefMan
External Links: USPTO, USPTO Assignment, Espacenet
Pharmaceutical kit
US D457246 S1
Images(8)
Previous page
Next page
Claims(1)
  1. The ornamental design for a pharmaceutical kit, as shown and described.
Description

FIG. 1 is an exploded perspective view, on a reduced scale, of a pharmaceutical kit showing our new design in the fully unfolded position with an uninserted insert card;

FIG. 2 is a full scale front plan view thereof;

FIG. 3 is a full scale end elevational view thereof;

FIG. 4 is a full scale rear plan view thereof;

FIG. 5 is a full scale right end elevational view thereof;

FIG. 6 is a full scale left end elevational view thereof;

FIG. 7 is a full scale front plan view of the insert card of the pharmaceutical kit shown in FIG. 1;

FIG. 8 is a full scale rear plan view of the insert card of the pharmaceutical kit shown in FIG. 1;

FIG. 9 is a full scale side elevational view of the insert card of the pharmaceutical kit shown in FIG. 1;

FIG. 10 is a full scale end elevational view of the insert card of the pharmaceutical kit shown in FIG. 1;

FIG. 11 is a full scale perspective view of the pharmaceutical kit shown in FIG. 1 in the fully folded position; and,

FIG. 12 is an exploded perspective view, on a reduced scale, in the fully unfolded position with a partially inserted insert card.

Non-Patent Citations
Reference
1Adami et al., 6th Int'l Symposium on Clinical Disorders of Bone and Mineral Metabolism, Nov. 1999, "Rationale for once weekly dosing regimens with alendronate for the treatment and prevention of osteoporosis", p. 48.
2Bone III et al., 6th Int'l Symposium on Clinical Disorders of Bone and Mineral Metabolism, Nov. 1999 ,"Alendronate 70 mg once weekly is therapeutically equivalent to alendronate 10 mg daily", p. 55.
3Copy of dispenser package and insert for Heartgard 30® (ivermectin) chewables, Merck & Co., Inc., Oct. 1988.
4Greenberg, Clin. Therap., vol. 6 (1984), "Overview of patient compliance with medication dosing: A literature Review", pp. 592-599.
5Schnitzer et al., Aging Clin. Exp. Res., vol. 12 (2000), pp. 1-12, "Therapeutic equivalence of alendronate 70 mg once-weekly and alendronate 10 mg daily in the treatment of osteoporosis".
Referenced by
Citing PatentFiling datePublication dateApplicantTitle
WO2003076303A1 *Mar 3, 2003Sep 18, 2003Ching Yi ChangPharmaceutical treatment blister card
Classifications
U.S. ClassificationD24/223